United Capital Financial Advisers LLC Increases Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

United Capital Financial Advisers LLC increased its holdings in Novo Nordisk A/S (NYSE:NVO) by 6.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 748,296 shares of the company’s stock after purchasing an additional 43,824 shares during the period. United Capital Financial Advisers LLC’s holdings in Novo Nordisk A/S were worth $38,193,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Comerica Securities Inc. grew its position in Novo Nordisk A/S by 12.0% during the fourth quarter. Comerica Securities Inc. now owns 11,443 shares of the company’s stock valued at $527,000 after acquiring an additional 1,223 shares during the period. Quantamental Technologies LLC purchased a new stake in Novo Nordisk A/S during the first quarter valued at about $41,000. Janus Henderson Group PLC grew its position in Novo Nordisk A/S by 11.4% during the first quarter. Janus Henderson Group PLC now owns 247,811 shares of the company’s stock valued at $12,963,000 after acquiring an additional 25,382 shares during the period. Cornerstone Advisors Inc. grew its position in Novo Nordisk A/S by 33.6% during the first quarter. Cornerstone Advisors Inc. now owns 5,689 shares of the company’s stock valued at $298,000 after acquiring an additional 1,432 shares during the period. Finally, Stephens Inc. AR grew its position in Novo Nordisk A/S by 10.3% during the first quarter. Stephens Inc. AR now owns 40,196 shares of the company’s stock valued at $2,103,000 after acquiring an additional 3,757 shares during the period. 7.36% of the stock is owned by institutional investors and hedge funds.

Shares of NVO traded down $0.25 during midday trading on Friday, reaching $49.42. 1,099,906 shares of the company were exchanged, compared to its average volume of 1,305,662. The stock has a 50-day moving average price of $50.81 and a 200-day moving average price of $49.93. The company has a market cap of $117.45 billion, a price-to-earnings ratio of 19.61, a P/E/G ratio of 2.11 and a beta of 0.57. Novo Nordisk A/S has a 1-year low of $41.23 and a 1-year high of $53.55. The company has a current ratio of 1.04, a quick ratio of 0.73 and a debt-to-equity ratio of 0.06.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Friday, August 9th. The company reported $0.61 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.61. The company had revenue of $4.52 billion for the quarter, compared to analysts’ expectations of $4.41 billion. Novo Nordisk A/S had a return on equity of 75.16% and a net margin of 32.16%. Equities research analysts anticipate that Novo Nordisk A/S will post 2.45 earnings per share for the current year.

The firm also recently declared a Semi-Annual dividend, which was paid on Tuesday, August 27th. Investors of record on Monday, August 19th were paid a $0.318 dividend. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 25.40%.

A number of equities research analysts have issued reports on the company. Jefferies Financial Group downgraded Novo Nordisk A/S from a “hold” rating to an “underperform” rating in a research report on Friday, August 30th. UBS Group reissued a “buy” rating and set a $355.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, June 19th. Barclays raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $51.85 price target for the company in a research report on Tuesday, June 11th. Pareto Securities upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Monday, August 5th. Finally, Deutsche Bank cut Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $52.42 price objective on the stock. in a research note on Thursday, June 20th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $159.65.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Featured Article: How to trade the most active stocks

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.